Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Tami D. John
- Target Recruit Count
- 8
- Registration Number
- NCT00578344
- Locations
- 🇺🇸
Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT00578643
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT00578292
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT00579111
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00555048
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
- Conditions
- Interventions
- Biological: anti-thymocyte globulinDrug: busulfanDrug: cyclophosphamideDrug: cyclosporineDrug: methotrexateDrug: methylprednisoloneDrug: tacrolimusOther: laboratory biomarker analysisOther: pharmacological studyProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 158
- Registration Number
- NCT00553202
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
- Conditions
- Interventions
- Biological: filgrastimDrug: CyclophosphamideDrug: BusulfanDrug: CyclosporineDrug: Fludarabine phosphateDrug: Mycophenolate MofetilDrug: MelphalanProcedure: allogeneic hematopoietic stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: Fractionated total body irradiationRadiation: total-body irradiation
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00547196
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
- Conditions
- Interventions
- Drug: cyclosporineDrug: cyclophosphamideDrug: busulfanDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: sirolimusDrug: tacrolimusProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 260
- Registration Number
- NCT00544115
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChildhood Acute Myeloid Leukemia in RemissionPreviously Treated Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00540995
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.